Atria Wealth Solutions Inc. Sells 274 Shares of Boston Scientific Co. (NYSE:BSX)

Atria Wealth Solutions Inc. lowered its position in Boston Scientific Co. (NYSE:BSX) by 2.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 11,484 shares of the medical equipment provider’s stock after selling 274 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Boston Scientific were worth $664,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Bruce G. Allen Investments LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at approximately $28,000. Venturi Wealth Management LLC raised its stake in shares of Boston Scientific by 58.0% in the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 215 shares during the last quarter. Motco raised its stake in shares of Boston Scientific by 136.3% in the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 372 shares during the last quarter. Cetera Trust Company N.A bought a new position in shares of Boston Scientific in the fourth quarter valued at approximately $43,000. Finally, Asset Dedication LLC raised its stake in shares of Boston Scientific by 42.6% in the third quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock valued at $41,000 after acquiring an additional 235 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares of the company’s stock, valued at approximately $2,690,551.22. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares of the company’s stock, valued at approximately $2,690,551.22. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the transaction, the executive vice president now owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 78,384 shares of company stock valued at $5,395,560. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX stock opened at $72.85 on Friday. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $74.39. The firm has a market capitalization of $106.88 billion, a price-to-earnings ratio of 61.22, a price-to-earnings-growth ratio of 2.48 and a beta of 0.77. The company has a quick ratio of 0.82, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. The firm has a fifty day moving average of $68.42 and a 200-day moving average of $61.27.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.51 by $0.04. The firm had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. During the same period in the prior year, the business earned $0.45 EPS. On average, equities research analysts forecast that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on BSX. UBS Group boosted their price objective on shares of Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. JPMorgan Chase & Co. boosted their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Citigroup boosted their price objective on shares of Boston Scientific from $79.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Finally, Raymond James boosted their price objective on shares of Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a research report on Thursday, April 25th. Three equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $75.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.